Literature DB >> 19265826

Getting a handle on Huntington's disease: silencing neurodegeneration.

Albert R La Spada1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19265826     DOI： 10.1038/nm0309-252

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

1.  Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

Authors:  A Yamamoto; J J Lucas; R Hen
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

Review 2.  From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS.

Authors:  D W Cleveland; J D Rothstein
Journal:  Nat Rev Neurosci       Date:  2001-11       Impact factor: 34.870

Review 3.  Progress in antisense technology.

Authors:  Stanley T Crooke
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

Review 4.  Silencing polyglutamine degeneration with RNAi.

Authors:  Nancy M Bonini; Albert R La Spada
Journal:  Neuron       Date:  2005-12-08       Impact factor: 17.173

5.  Antisense oligonucleotide therapy for neurodegenerative disease.

Authors:  Richard A Smith; Timothy M Miller; Koji Yamanaka; Brett P Monia; Thomas P Condon; Gene Hung; Christian S Lobsiger; Chris M Ward; Melissa McAlonis-Downes; Hongbing Wei; Ed V Wancewicz; C Frank Bennett; Don W Cleveland
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

Review 6.  Genomic rearrangements and gene copy-number alterations as a cause of nervous system disorders.

Authors:  Jennifer A Lee; James R Lupski
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

7.  RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.

Authors:  Haibin Xia; Qinwen Mao; Steven L Eliason; Scott Q Harper; Inês H Martins; Harry T Orr; Henry L Paulson; Linda Yang; Robert M Kotin; Beverly L Davidson
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

Review 8.  Polyglutamines placed into context.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

Review 9.  Toxic proteins in neurodegenerative disease.

Authors:  J Paul Taylor; John Hardy; Kenneth H Fischbeck
Journal:  Science       Date:  2002-06-14       Impact factor: 47.728

Review 10.  Normal huntingtin function: an alternative approach to Huntington's disease.

Authors:  Elena Cattaneo; Chiara Zuccato; Marzia Tartari
Journal:  Nat Rev Neurosci       Date:  2005-12       Impact factor: 34.870
View more
  3 in total

1.  Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.

Authors:  Jiaxin Hu; Jing Liu; David R Corey
Journal:  Chem Biol       Date:  2010-11-24

2.  Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy.

Authors:  Constanza J Cortes; Shuo-Chien Ling; Ling T Guo; Gene Hung; Taiji Tsunemi; Linda Ly; Seiya Tokunaga; Edith Lopez; Bryce L Sopher; C Frank Bennett; G Diane Shelton; Don W Cleveland; Albert R La Spada
Journal:  Neuron       Date:  2014-04-16       Impact factor: 17.173

3.  PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease.

Authors:  Jun Wan Shin; Eun Pyo Hong; Seri S Park; Doo Eun Choi; Sophia Zeng; Richard Z Chen; Jong-Min Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-14       Impact factor: 5.849
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.